INmune Bio, Inc.
INmune Bio, Inc. (INMB) Stock Overview
Explore INmune Bio, Inc.’s financial performance, market position, analyst ratings, and future outlook.
INMB Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of INmune Bio, Inc. (INMB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $5.91.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.87 and a market capitalization of 123.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Raymond Joseph Tesi
13
225 NE Mizner Boulevard, Boca Raton, FL
2019